Trial Profile
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Juvenile myelomonocytic leukaemia
- Focus Therapeutic Use
- 12 Dec 2023 Primary endpoint has been met. (Objective response), as per Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Status changed from active, no longer recruiting to completed.
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition